Having declared mpox a public health emergency of international concern (PHEIC), the World Health Organization has called on countries to take steps to make mpox vaccines available for primary prevention and post-exposure vaccination for people at most risk of contracting the disease.
WHO Urges Countries To Curb Spread Of Mpox With Vaccines, Therapeutics & Other Actions
The WHO’s emergency committee has warned of a lack of understanding of the epidemiology of mpox, the limited availability of vaccines, and the complexities of donations and procurement.
More from International
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
• By
The Australian Therapeutic Goods Administration proposed a narrower indication that Eisai rejected.
More from Middle East & Africa
• By
The World Health Organization has also prequalified the Bavarian Nordic vaccine to enable broader and timely access.
• By
Companies marketing pharmaceutical products in Saudi Arabia are being urged to prepare for upcoming mandatory pharmacoeconomic assessments to demonstrate the added value of their drugs over existing treatments.
• By
The Democratic Republic of Congo, the country worst hit by the mpox crisis, has now received the first batch of vaccines for the disease. Meanwhile, the World Health Organization is expected to complete its review for emergency use listing of mpox vaccines soon.